Breaking News Instant updates and real-time market news.

BIVV

Bioverativ

$64.11

1.36 (2.17%)

, JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

12:08
01/22/18
01/22
12:08
01/22/18
12:08

On The Fly: Top stock stories at midday

Stocks opened mixed, with the Dow lower and the S&P and Nasdaq in positive territory. All three major averages have turned green near noon as the market shakes off the government shutdown, which is in its third day but looks poised to end if media reports breaking in the last few minutes are believed. ECONOMIC EVENTS: In the U.S., the Chicago Fed's National Activity index rose to 0.27 in December. A positive index reading corresponds to growth above trend. COMPANY NEWS: It was a "merger Monday" on Wall Street as three multi-billion dollar deals dominated the headlines. The largest in terms of dollar value was Sanofi's (SNY) agreement to acquire all of the outstanding shares of Bioverativ (BIVV) for $105 per share in cash, representing an equity value of approximately $11.6B. Also in the drugmaking space, Celgene (CELG) announced a deal to acquire Juno Therapeutics (JUNO) for $87 per share in cash, or a total of approximately $9B, net of cash and marketable securities acquired and Juno shares already owned by Celgene. In the insurance sector, American International Group (AIG) agreed to buy Validus Holdings (VR), a provider of reinsurance, primary insurance, and asset management services. Holders of Validus common shares will receive cash consideration of $68.00 per share, for an aggregate transaction value of $5.56B. If post-deal announcement share price is used as any measure of investor reaction, Sanofi's deal garnered the worst reaction, sliding about 3% in the wake of its news. AIG and Celgene shares, meanwhile, are both fractionally lower near noon. MAJOR MOVERS: Among the notable gainers was Array Biopharma (ARRY), which gained 19% after the company presented updated data from the safety lead-in portion of the Phase 3 BEACON trial at a clinical meeting. Also higher was FirstEnergy (FE), which gained 13% after announcing a $2.5B investment in the company that includes $1.62B in mandatory convertible preferred equity and $850M of common equity from investors including affiliates of Elliott Management. Among the noteworthy losers was Idera Pharmaceuticals (IDRA), which dropped 22% after announcing a definitive merger agreement to form a new enterprise with BioCryst Pharmaceuticals (BCRX) focused on the development and commercialization of medicines to serve more patients suffering from rare diseases. Also lower following its earnings report was Sanmina (SANM), which fell 24%. INDEXES: Near midday, the Dow was up 52.94, or 0.2%, to 26,124.66, the Nasdaq was up 49.98, or 0.68%, to 7,386.36, and the S&P 500 was up 12.23, or 0.44%, to 2,822.53.

BIVV

Bioverativ

$64.11

1.36 (2.17%)

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

VR

Validus

$67.50

20.775 (44.47%)

SNY

Sanofi

$43.23

-1.37 (-3.07%)

CELG

Celgene

$102.65

0.93 (0.91%)

AIG

AIG

$61.03

-0.525 (-0.85%)

IDRA

Idera Pharmaceuticals

$2.55

0.145 (6.03%)

BCRX

BioCryst

$5.59

-0.09 (-1.58%)

SANM

Sanmina

$35.45

0.5 (1.43%)

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

FE

FirstEnergy

$33.23

3.83 (13.03%)

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 29

    Jan

  • 02

    Feb

  • 09

    Feb

  • 14

    Feb

  • 16

    Feb

  • 20

    Feb

  • 21

    Feb

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

  • 30

    Jun

  • 30

    Jun

BIVV Bioverativ
$64.11

1.36 (2.17%)

01/18/18
RBCM
01/18/18
NO CHANGE
Target $68
RBCM
Sector Perform
Bioverativ price target raised to $68 from $57 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Bioverativ to $68, saying that he anticipates a strong FY18 guidance that will show the company trading at an attractive valuation relative to peers. The analyst keeps his Sector Perform rating however, citing the "continued debate around Eloctate's longer term erosion potential with Hemlibra's HAVEN-3 full results in the broader non-inhibitor hemeA population looming".
01/18/18
FBCO
01/18/18
INITIATION
Target $65
FBCO
Neutral
Bioverativ assumed with a Neutral at Credit Suisse
Credit Suisse analyst Martin Auster assumed coverage of Bioverativ with a Neutral rating and $65 price target. The analyst is cautious on the growth prospects for the company's hemophilia business.
01/18/18
JEFF
01/18/18
NO CHANGE
Target $79
JEFF
Buy
Bioverativ price target raised to $79 from $70 at Jefferies
Jefferies analyst Eun Yang raised her price target for Bioverativ to $79 after speaking to management and keeps a Buy rating on the shares. The company is confident of Eloctate growth prospects in hemophilia A, and its growth assumptions do not seem aggressive, Yang tells investors in a research note. The analyst's new price target largely reflects Bioverativ's benefits from U.S. tax reform.
12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.
JUNO Juno Therapeutics
$67.81

-3.56 (-4.99%)

01/22/18
PIPR
01/22/18
NO CHANGE
PIPR
Neutral
Celgene set high bar for Juno deal, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond believes the acquisition of Juno Therapeutics (JUNO) makes good strategic sense for Celgene (CELG). The analyst, however, believes Celgene set a "relatively high" bar by guiding to peak revenue of $3B for lead candidate JCAR017 in non-Hodgkin lymphoma. Raymond keeps a Neutral rating on Celgene shares.
01/22/18
GUGG
01/22/18
DOWNGRADE
GUGG
Neutral
Juno Therapeutics downgraded to Neutral from Buy at Guggenheim
Juno Therapeutics (JUNO) is being acquired by Celgene (CELG) for $87 per share in cash.
01/22/18
JEFF
01/22/18
NO CHANGE
Target $125
JEFF
Buy
Celgene, Juno deal 'smart' if more than JCAR017 plays out, says Jefferies
Following the announced acquisition of Juno Therapeutics (JUNO) by Celgene (CELG), Jefferies analyst Michael Yee notes that in the short term, the Street will debate whether pivotal Juno data coming will look better than Kite's (GILD) Yescarta and whether JCAR17 is truly differentiated. Longer-term, the analyst believes this is a deal hinged on Celgene's confidence in going "all in" on cell therapy over the next 5-10 years. Like Gilead/Kite, this will be a "smart deal" if more than just JCAR17 plays out, he contends, adding that he thinks it will over next few years. Yee reiterates a Buy rating and $125 price target on Celgene's shares.
01/22/18
NEED
01/22/18
DOWNGRADE
NEED
Hold
Juno Therapeutics downgraded to Hold from Buy at Needham
Needham analyst Chad Messer downgraded Juno Therapeutics (JUNO) to Hold from Buy after the company agreed to be acquired by Celgene (CELG) for $87 per share. He does not expect additional bidders and thinks the deal will close under the current terms, Messer tells investors.
VR Validus
$67.50

20.775 (44.47%)

09/21/17
UBSW
09/21/17
NO CHANGE
Target $50
UBSW
Neutral
Validus net exposure to hurricanes lower than anticipated, says UBS
After hosting meetings with Validus' CFO, UBS analyst Brian Meredith said his prior loss estimate for Hurricane Harvey and Irma was too high given the company's amount of retrocessional and reinsurance protection and its minimal exposure to the Caribbean. He lowered his forecast for Q3 catastrophe losses to $412M from $613M. Meredith keeps a Neutral rating on Validus shares.
01/04/18
KBWI
01/04/18
UPGRADE
Target $55
KBWI
Outperform
Validus upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Meyer Shields upgraded Validus to Outperform with a $55 price target.
01/22/18
FBCO
01/22/18
NO CHANGE
Target $73
FBCO
Outperform
Validus acquisition could add 30c-40c to AIG EPS in 2019, says Credit Suisse
Credit Suisse analyst Ryan Tunis notes that AIG (AIG) announced that it is acquiring Validus (VR) for $68 per share all cash. As a positive, the analyst says the deal shows that AIG has no intention of sitting on capital and that the company feels comfortable that it has on balance sheet capital to deploy following Q3 hurricanes and in front of a Q4 reserve review. Tunis initial expectation is that the deal could add 30c-40c to AIG EPS in 2019. He does not think this is the last M&A event for AIG over the next several quarters, but this deal has AIG going deeper into P&C. The analyst reiterates an Outperform rating and $73 price target on the AIG shares.
01/22/18
WELS
01/22/18
NO CHANGE
WELS
Outperform
Voya has other potential suitors, selloff unwarranted, says Wells Fargo
Wells Fargo analyst Sean Dargan does not think AIG's (AIG) acquisition today of Validus (VR) warrants a selloff in Voya Financial (VOYA) shares. Earlier this month, media reports indicated AIG was in talks to acquire Voya but that the talks broke down in November over price. There are other potential buyers for Voya's "go-forward business mix of investment management, retirement and group benefits," Dargan tells investors in a research note. One potential party that might be interested in Voya is Nippon Life of Japan, who publicly proclaimed a strategy of international acquisitions, the analyst contends. Dargan has an Outperform rating on Voya shares.
SNY Sanofi
$43.23

-1.37 (-3.07%)

12/01/17
MSCO
12/01/17
DOWNGRADE
MSCO
Underweight
Sanofi downgraded to Underweight from Overweight at Morgan Stanley
12/06/17
BOFA
12/06/17
DOWNGRADE
BOFA
Neutral
Sanofi downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Graham Perry downgraded Sanofi to Neutral citing valuation and lack of earnings momentum into 2018.
12/28/17
ARGS
12/28/17
NO CHANGE
Target $470
ARGS
Buy
Regeneron price target lowered to $470 from $540 at Argus
Argus analyst Jasper Hellweg lowered his price target on Regeneron (REGN) to $470 to reflect some of the recent weakness in the stock, but keeps his Buy rating. Hellweg says that while the company's growth has slowed in recent years, it continues to benefit from sales of Eylea, collaboration agreements with Sanofi (SNY) and Bayer (BAYRY) as well as a strong new product pipeline.
01/07/18
PIPR
01/07/18
NO CHANGE
Target $182
PIPR
Overweight
Deal with Sanofi 'good' for Alnylam, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that under a strategic alliance restructuring, Alnylam (ALNY) is gaining global rights to patisiran and ALN-TTRsc02, and Sanofi (SNY) gains global fitusiran rights. The analyst anticipates patisiran FDA approval in mid'18 and in Europe in late'18. Tenthoff views this as a "good deal" for Alnylam as the company will control global TTR amyloidosis development and commercialization. He reiterates an Overweight rating and $182 price target on Alnylam shares.
CELG Celgene
$102.65

0.93 (0.91%)

01/18/18
SBSH
01/18/18
DOWNGRADE
Target $81
SBSH
Neutral
Citi downgrades Juno to Neutral, says potential takeover priced in
Citi analyst Robyn Karnauskas last night downgraded Juno Therapeutics (JUNO) to Neutral from Buy while raising her price target for the shares to $81 from $59. Juno closed yesterday up 52%, or $23.65, to $69.25 after the Wall Street Journal reported that Celgene (CELG) is in talks to acquire the company. When the story broke, Karnauskas said in a research note that Juno could be worth $110 per share in a takeover. She believes, however, that for Celgene, a deal makes sense in the $80-$85 per share range. The analyst expects Juno to trade with an M&A premium at $81 per share. With the recent 49% jump in shares, and the stock now trading within 17% of our takeover price, Karnauskas tells investors in a research note.
AIG AIG
$61.03

-0.525 (-0.85%)

01/09/18
EVER
01/09/18
NO CHANGE
EVER
Evercore ISI says reported AIG interest a 'pretty bullish signal' for Voya value
After Bloomberg said that AIG (AIG) had previously held talks to acquire Voya Financial (VOYA) in a deal valued at more than $10B, Evercore ISI analyst Thomas Gallagher said he reads this as a sign that AIG is open to large scale M&A and as "a pretty bullish signal" for the private market value of Voya being considerably above its current share price.
12/06/17
12/06/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AIG (AIG) upgraded to Hold from Sell at Deutsche Bank with analyst Joshua Shanker sayign the stock "might have found a bottom" after dropping 8% since the third quarter results on November 2. Brown & Brown (BRO) upgraded to Buy from Hold at SunTrust with analyst Mark Hughes saying the company stands to benefit from commission gains in the Florida market, contribution from the company's sales incentive program, reduced investments costs, and the anticipated tax reform impact which could add up to 55c to the fiscal 2019 earnings per share target of $2.25. 3. L3 Technologies (LLL) upgraded to Outperform from Sector Perform at RBC Capital with analyst Matt McConnell citing the company's investor day presentation. McConnell says the event highlighted the company's position combining the "best-in-defense runway for operating margin improvement, near-term organic growth acceleration, and bolt-on M&A potential". 4. Carnival (CCL) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Jamie Rollo stating that the firm's survey of U.S. travel agents suggested strong demand for cruises in November, which he notes is usually a slow month for bookings. 5. Express Scripts (ESRX) upgraded to Market Perform from Underperform at Bernstein with the firm citing improved upside risks from potential policy and competitor actions and valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IDRA Idera Pharmaceuticals
$2.55

0.145 (6.03%)

11/09/17
HCWC
11/09/17
INITIATION
Target $4
HCWC
Buy
Idera Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Idera Pharmaceuticals with a Buy rating and $4 price target. The company's two lead products have "significant potential in the fast growing immunotherapy market," the analyst contends.
11/09/17
11/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AnaptysBio (ANAB) initiated with a Buy at Jefferies. 2. Regenxbio (RGNX) resumed with an Overweight at Morgan Stanley. 3. GTx (GTXI) initiated with a Buy at Stifel. 4. Idera Pharmaceuticals (IDRA) initiated with a Buy at H.C. Wainwright. 5. Nektar (NKTR) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/17
PIPR
11/09/17
NO CHANGE
Target $4
PIPR
Overweight
Piper reiterates Overweight rating on Idera after IMO-2125 trial update
After Idera Pharmaceuticals reported a 5th unconfirmed RECIST response in its ongoing IMO-2125 plus Yervoy combo trial in PD-1 refractory metastatic melanoma, bringing the ORR to 50%, Piper Jaffray analyst Edward Tenthoff reiterated his Overweight rating and $4 price target on the stock, which is up 15% to $2.03 in midday trading.
04/25/17
04/25/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sony (SNE) initiated with an Outperform at Bernstein. 2. Rockwell Collins (COL) reinstated with a Sell at Goldman Sachs. 3. Idera Pharmaceuticals (IDRA) initiated with an Outperform at Baird. 4. GasLog (GLOG) initiated with an Outperform at Credit Suisse. 5. Fitbit (FIT) initiated with a Buy at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BCRX BioCryst
$5.59

-0.09 (-1.58%)

01/02/18
RBCM
01/02/18
UPGRADE
Target $8
RBCM
Outperform
BioCryst upgraded to Outperform at RBC Capital on BCX7353 performance
As reported earlier, RBC Capital analyst Brian Abrahams upgraded BioCryst to Outperform from Sector Perform and raised his price target to $8 from $6. Abrahams says the lead drug BCX7353 showed a clear reduction in hereditary angioedema attacks in its phase 2 study, while its lack of dose dependence is "legitimately explainable by misidentification of GI side effects at the higher doses". The analyst adds that the recent FDA precedent also implies a "relatively low bar for approvals of drugs to treat rare, potentially fatal diseases".
11/28/17
JMPS
11/28/17
NO CHANGE
Target $12
JMPS
Outperform
JMP Securities finds doctors 'bullish' on BioCryst HAE drug
JMP Securities analyst Liisa Bayko said her survey of allergists found them to be "bullish" on BioCryst's lead asset, BCX7353, even in the context of other highly effective hereditary angioedema treatment options. This physician enthusiasm is disconnected from BioCryst's valuation, contends Bayko, who reiterates her Outperform rating and $12 price target on the stock.
12/20/17
LEHM
12/20/17
INITIATION
Target $6
LEHM
Equal Weight
BioCryst initiated with an Equal Weight at Barclays
Barclays analyst Gena Wang started BioCryst Pharmaceuticals with an Equal Weight rating and $6 price target. The analyst sees a lack of meaningful clinical catalysts in 2018 and some risk around the company's Phase 3 trial for BCX7353 in hereditary angioedema.
01/02/18
RBCM
01/02/18
UPGRADE
RBCM
Outperform
BioCryst upgraded to Outperform from Sector Perform at RBC Capital
SANM Sanmina
$35.45

0.5 (1.43%)

12/18/17
CHLM
12/18/17
UPGRADE
Target $44
CHLM
Buy
Sanmina upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Christian Schwab upgraded Sanmina to Buy from Hold on attractive risk/reward. The analyst also raised his price target on the shares to $44 from $43.
11/02/17
ARGS
11/02/17
DOWNGRADE
ARGS
Hold
Sanmina downgraded to Hold from Buy at Argus
01/22/18
RBCM
01/22/18
NO CHANGE
Target $31
RBCM
Sector Perform
Sanmina price target lowered to $31 from $38 at RBC Capital
RBC Capital analyst Mitch Steves lowered his price target on Sanmina to $31 after below-consensus preliminary Q1 results. The analyst says that continued softness in the optical segment is likely behind the weakness, adding that he needs to see margin improvement to be more constructive on the stock. Steves keeps his Sector Perform rating on Sanmina.
01/22/18
CHLM
01/22/18
NO CHANGE
Target $37
CHLM
Buy
Sanmina target lowered to $37 on 'disappointing' results at Craig-Hallum
Craig-Hallum analyst Christian Schwab lowered his price target for Sanmina shares to $37 citing this morning's lower than expected Q1 results and Q2 guidance. The analyst views the results as "disappointing," but keeps a Buy rating on the shares with the stock down 25% in morning trading. Schwab expects to see a "material recovery" in gross margins at "some point" as Sanmina works through engineering changes to new programs that are impacting yields.
ARRY Array BioPharma
$13.14

0.26 (2.02%)

01/22/18
01/22/18
UPGRADE
Target $19

Outperform
Array BioPharma upgraded to Outperform at Leerink
As previously reported, Leerink analyst Michael Schmidt upgraded Array BioPharma to Outperform from Market Perform on higher conviction on BRAF+ CRC. The analyst also raised his price target on the shares to $19 from $12.
01/22/18
LEER
01/22/18
UPGRADE
LEER
Outperform
Array BioPharma upgraded to Outperform from Market Perform at Leerink
12/22/17
JEFF
12/22/17
NO CHANGE
Target $13
JEFF
Buy
Array BioPharma price target raised to $13 from $9 at Jefferies
Jefferies analyst Eun Yang raised her price target for Array BioPharma to $13 citing the potential for the Binimetinib/anti-PD-1 colorectal cancer. This could be the biggest value driver for Array, Yang tells investors in a research note. The analyst now assumes 30% probability-adjusted peak sales of $1.2B for binimetinib. She keeps a Buy rating on Array.
01/22/18
STFL
01/22/18
NO CHANGE
Target $20
STFL
Buy
Array BioPharma price target raised to $20 from $15 at Stifel
Stifel analyst Stephen Willey said he is incrementally more positive on Array Biopharma after the company presented updated data from the safety lead-in portion of the Phase 3 BEACON trial at a clinical meeting. He views the new data as "impressive, and clearly superior," to the SWOG 1406 data, Willey tells investors. The analyst raised his price target on Array to $20 from $15 and keeps a Buy rating on the shares.
FE FirstEnergy
$33.23

3.83 (13.03%)

01/22/18
KEYB
01/22/18
NO CHANGE
KEYB
FirstEnergy cash infusion removes overhang, provides path forward, says KeyBanc
KeyBanc analyst Paul Ridzon notes that FirstEnergy announced a cash infusion of $2.5B to strengthen the balance sheet, fund pensions, and provide capital for regulated investment. The analyst believes this removes an equity overhang and provides visibility to the company's transition to a pure play regulated utility.
10/17/17
DBAB
10/17/17
UPGRADE
DBAB
Buy
FirstEnergy upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Jonathan Arnold upgraded FirstEnergy to Buy and raised his price target for the shares to $35 from $34.
08/14/17
EVER
08/14/17
UPGRADE
EVER
Outperform
FirstEnergy upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Greg Gordon upgraded FirstEnergy to Outperform with a $35 price target saying he is more comfortable with the FES bankruptcy and financial exposure and said shares remain at a "meaningful" discount to peers.
07/14/17
07/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Boeing (BA) upgraded to Overweight from Neutral at JPMorgan with analyst Seth Seifman saying Boeing is among the stocks best positioned to benefit from positive aerospace fundamentals. 2. Wal-Mart (WMT) and Ulta Beauty (ULTA) were upgraded to Conviction Buy from Neutral at Goldman Sachs. 3. Nutanix (NTNX) upgraded to Conviction Buy, viewed as M&A target at Goldman Sachs with analyst Simona Jankowski saying the company is a "once-in-decade tech infrastructure" that will benefit from double digit growth, high gross margins and significant operating leverage. 4. Ross Stores (ROST) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Dana Telsey saying the company's valuation is attractive and expects focused execution of its off-price model to deliver best everyday value to customers, which should allow it to be a relative share winner. 5. FirstEnergy (FE) upgraded to Hold from Trim at Tudor Pickering. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:26
02/24/18
02/24
16:26
02/24/18
16:26
Hot Stocks
Buffett believes Berkshire can handle $400B mega-catastrophe »

In his annual letter to…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:19
02/24/18
02/24
16:19
02/24/18
16:19
Periodicals
Buffet says laments inability to find targets for Berkshire to buy, Reuters says »

Warren Buffett lamented…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:16
02/24/18
02/24
16:16
02/24/18
16:16
Periodicals
Berkshire Hathaway reports record profit fueled by tax reform, Reuters says »

Berkshire Hathaway…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$32.66

0.55 (1.71%)

16:12
02/24/18
02/24
16:12
02/24/18
16:12
Periodicals
Twitter's SoundCloud investment officially wiped out, Recode reports »

Twitter has written off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

AAPL

Apple

$175.50

3 (1.74%)

16:08
02/24/18
02/24
16:08
02/24/18
16:08
Periodicals
Apple to store sensitive encryption keys in China, WSJ reports »

Apple will start to store…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.98

0.09 (0.22%)

16:00
02/24/18
02/24
16:00
02/24/18
16:00
Periodicals
Volkswagen's U.S. unit settles emissions suit, Reuters reports »

Volkswagen's unit in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$53.46

0.91 (1.73%)

, UAL

United Continental

$67.57

0.87 (1.30%)

15:56
02/24/18
02/24
15:56
02/24/18
15:56
Periodicals
Delta, United Airlines cut ties with NRA, Reuters reports »

Delta Air Lines (DAL) and…

DAL

Delta Air Lines

$53.46

0.91 (1.73%)

UAL

United Continental

$67.57

0.87 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 30

    May

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

15:53
02/24/18
02/24
15:53
02/24/18
15:53
Earnings
Berkshire Hathaway reports Q4 operating EPS $3,338, consensus $2,622.23 »

Reports FY17 operating…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$94.70

0.33 (0.35%)

, T

AT&T

$36.72

0.25 (0.69%)

15:44
02/24/18
02/24
15:44
02/24/18
15:44
Periodicals
May be time to consider Time Warner, Barron's says »

Time Warner (TWX) shares…

TWX

Time Warner

$94.70

0.33 (0.35%)

T

AT&T

$36.72

0.25 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 23

    Apr

JKHY

Jack Henry

$121.95

1.79 (1.49%)

12:59
02/24/18
02/24
12:59
02/24/18
12:59
Conference/Events
Jack Henry management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

PFBC

Preferred Bank

$64.05

0.86 (1.36%)

12:52
02/24/18
02/24
12:52
02/24/18
12:52
Conference/Events
Preferred Bank management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Mar

  • 24

    Sep

R

Ryder

$74.54

0.19 (0.26%)

12:47
02/24/18
02/24
12:47
02/24/18
12:47
Conference/Events
Ryder management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

ASPU

Aspen Group

$8.85

1.48 (20.08%)

12:29
02/24/18
02/24
12:29
02/24/18
12:29
Conference/Events
Aspen Group to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

TWTR

Twitter

$32.66

0.55 (1.71%)

, AOBC

American Outdoor Brands

$10.00

-0.12 (-1.19%)

10:47
02/24/18
02/24
10:47
02/24/18
10:47
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWTR

Twitter

$32.66

0.55 (1.71%)

AOBC

American Outdoor Brands

$10.00

-0.12 (-1.19%)

RGR

Sturm, Ruger

$49.90

0.9 (1.84%)

X

U.S. Steel

$43.52

0.54 (1.26%)

STLD

Steel Dynamics

$47.47

-0.53 (-1.10%)

NUE

Nucor

$66.94

-0.01 (-0.01%)

AKS

AK Steel

$5.50

-0.12 (-2.14%)

AET

Aetna

$175.55

0.49 (0.28%)

ANTM

Anthem

$235.24

1.56 (0.67%)

CNC

Centene

$100.45

0.96 (0.96%)

CI

Cigna

$194.79

2.89 (1.51%)

HNT

Health Net

HUM

Humana

$271.19

3.38 (1.26%)

MOH

Molina Healthcare

$72.94

1.38 (1.93%)

UNH

UnitedHealth

$230.16

3.07 (1.35%)

WCG

WellCare

$192.05

0.03 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 01

    Mar

  • 07

    Mar

  • 13

    Mar

  • 16

    Apr

  • 30

    May

DBX

Dropbox

, SNAP

Snap

$17.45

-0.06 (-0.34%)

09:49
02/24/18
02/24
09:49
02/24/18
09:49
Periodicals
Dropbox IPO bodes well, Barron's says »

In a follow-up article…

DBX

Dropbox

SNAP

Snap

$17.45

-0.06 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

IPG

Interpublic Group

$24.24

0.3 (1.25%)

, OMC

Omnicom

$77.31

0.52 (0.68%)

09:42
02/24/18
02/24
09:42
02/24/18
09:42
Periodicals
Advertising companies cheaper than usual, Barron's says »

After a tumble last year,…

IPG

Interpublic Group

$24.24

0.3 (1.25%)

OMC

Omnicom

$77.31

0.52 (0.68%)

PUBGY

Publicis

$18.82

0.09 (0.48%)

WPP

WPP

$95.30

0.93 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 05

    Mar

MSFT

Microsoft

$94.06

2.33 (2.54%)

, INTC

Intel

$47.73

1.93 (4.21%)

09:36
02/24/18
02/24
09:36
02/24/18
09:36
Periodicals
Quantum computing soon to be reality, Barron's says »

Microsoft (MSFT) predicts…

MSFT

Microsoft

$94.06

2.33 (2.54%)

INTC

Intel

$47.73

1.93 (4.21%)

NVDA

Nvidia

$245.93

3.78 (1.56%)

MU

Micron

$46.53

2.28 (5.15%)

GOOG

Alphabet

$1,126.79

20.16 (1.82%)

GOOGL

Alphabet Class A

$1,128.09

18.19 (1.64%)

AMZN

Amazon.com

$1,500.00

14.66 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 28

    Feb

  • 07

    Mar

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 30

    May

AMZN

Amazon.com

$1,500.00

14.66 (0.99%)

09:26
02/24/18
02/24
09:26
02/24/18
09:26
Periodicals
Many downsides when Amazon's HQ2 comes to town, Barron's says »

As Amazon decides on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

BHGE

Baker Hughes

$28.03

-0.01 (-0.04%)

04:55
02/24/18
02/24
04:55
02/24/18
04:55
Conference/Events
Baker Hughes management to meet with UBS »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

GE

General Electric

$14.49

-0.01 (-0.07%)

18:49
02/23/18
02/23
18:49
02/23/18
18:49
Periodicals
General Electric could face DOJ action over subprime mortgages, Reuters says »

General Electric may face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

18:30
02/23/18
02/23
18:30
02/23/18
18:30
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

, CMD

Cantel Medical

$115.34

2.45 (2.17%)

18:03
02/23/18
02/23
18:03
02/23/18
18:03
Periodicals
J&J sterilization unit draws bids from Cantel Medical, Medtronic, Bloomberg says »

Cantel Medical (CMD) and…

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

CMD

Cantel Medical

$115.34

2.45 (2.17%)

MDT

Medtronic

$80.39

-0.02 (-0.02%)

KKR

KKR

$21.96

0.18 (0.83%)

CG

Carlyle Group

$23.15

-0.1 (-0.43%)

MMM

3M

$237.02

1.02 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 08

    Mar

  • 14

    Mar

  • 23

    Mar

  • 23

    Apr

  • 30

    May

AET

Aetna

$175.55

0.49 (0.28%)

, CVS

CVS Health

$68.16

0.16 (0.24%)

18:00
02/23/18
02/23
18:00
02/23/18
18:00
Hot Stocks
Aetna: CVS deal part of long-term solution toward value-based system »

According to prepared…

AET

Aetna

$175.55

0.49 (0.28%)

CVS

CVS Health

$68.16

0.16 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 30

    May

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:56
02/23/18
02/23
17:56
02/23/18
17:56
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:55
02/23/18
02/23
17:55
02/23/18
17:55
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.